198 related articles for article (PubMed ID: 24060641)
1. Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.
Patel HD; Feng Z; Landis P; Trock BJ; Epstein JI; Carter HB
J Urol; 2014 Mar; 191(3):629-37. PubMed ID: 24060641
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
3. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Cooperberg MR; Zheng Y; Faino AV; Newcomb LF; Zhu K; Cowan JE; Brooks JD; Dash A; Gleave ME; Martin F; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Carroll PR; Lin DW
JAMA Oncol; 2020 Oct; 6(10):e203187. PubMed ID: 32852532
[TBL] [Abstract][Full Text] [Related]
4. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract][Full Text] [Related]
5. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
6. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
[TBL] [Abstract][Full Text] [Related]
8. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
[TBL] [Abstract][Full Text] [Related]
10. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer.
Welty CJ; Cowan JE; Nguyen H; Shinohara K; Perez N; Greene KL; Chan JM; Meng MV; Simko JP; Cooperberg MR; Carroll PR
J Urol; 2015 Mar; 193(3):807-11. PubMed ID: 25261803
[TBL] [Abstract][Full Text] [Related]
11. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.
Tosoian JJ; Loeb S; Feng Z; Isharwal S; Landis P; Elliot DJ; Veltri R; Epstein JI; Partin AW; Carter HB; Trock B; Sokoll LJ
J Urol; 2012 Oct; 188(4):1131-6. PubMed ID: 22901577
[TBL] [Abstract][Full Text] [Related]
12. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Adamy A; Yee DS; Matsushita K; Maschino A; Cronin A; Vickers A; Guillonneau B; Scardino PT; Eastham JA
J Urol; 2011 Feb; 185(2):477-82. PubMed ID: 21167529
[TBL] [Abstract][Full Text] [Related]
13. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
14. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.
Ploussard G; de la Taille A; Terry S; Allory Y; Ouzaïd I; Vacherot F; Abbou CC; Salomon L
Urol Oncol; 2013 Oct; 31(7):1060-6. PubMed ID: 22300755
[TBL] [Abstract][Full Text] [Related]
15. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
[TBL] [Abstract][Full Text] [Related]
17. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
[TBL] [Abstract][Full Text] [Related]
18. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
19. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
[TBL] [Abstract][Full Text] [Related]
20. Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Marenghi C; Alvisi MF; Palorini F; Avuzzi B; Badenchini F; Bedini N; Bellardita L; Biasoni D; Bosetti D; Casale A; Catanzaro M; Colecchia M; De Luca L; Donegani S; Dordoni P; Lanocita R; Maffezzini M; Magnani T; Menichetti J; Messina A; Morlino S; Paolini B; Rancati T; Stagni S; Tesone A; Torelli T; Tulli Baldoin E; Vaiani M; Villa S; Villa S; Zaffaroni N; Nicolai N; Salvioni R; Valdagni R
Tumori; 2017 Sep; 103(5):464-474. PubMed ID: 28623636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]